FOXP3 and hepatocellular carcinoma: The evidence for an immunoinhibitory Treg–pDC interaction in HCC patients has been substantiated by a working group from Rotterdam: CD4+ FoxP3- IL-13- IL-10+ Treg1 cells (CD49b+ and LAG-3+) inhibited T cell responses in an IL-10 dependent manner.